wegovy

German researchers are making waves with a cutting-edge 'Trojan horse' obesity drug that has eclipsed current frontrunners in trials with mice. The innovative formula decreases appetite and weight significantly while also enhancing blood sugar levels and insulin sensitivity. Utilizing hormone mimics for precise cellular targeting, this approach minimizes unwanted side effects and presents a multifaceted method for combating obesity.

Polycystic ovary syndrome (PCOS) is now polyendocrine metabolic ovarian syndrome (PMOS), reflecting its hormonal and metabolic nature. Research highlights its endocrine roots, impacting insulin and other hormones, not just ovaries. This reclassification aims for earlier diagnosis and better management, emphasizing metabolic health alongside reproductive concerns for affected women.

Experiencing hair loss while losing weight is a common physiological reaction as the body enters 'survival mode.' Rapid weight loss, often triggered by extreme diets or weight-loss medications, can push hair follicles into a resting phase. Let's know more about this issue.

Affordable generic versions of Ozempic and wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging Eli Lilly's Mounjaro, with generics and lower pricing boosting semaglutide's market position.

New research reveals genes influence weight loss and nausea from Ozempic and Mounjaro. A study of nearly 28,000 people found specific genetic variants predict drug effectiveness and side effects. This breakthrough could lead to personalized prescriptions, helping doctors tailor treatments for millions. Doctors may soon use genetic tests to set realistic expectations and choose the best drug for each patient.

As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships

The FDA has approved a daily pill version of Novo Nordisk's wegovy, offering an oral alternative to injectable weight-loss drugs. Containing semaglutide, the pill demonstrated similar weight loss and side-effect profiles to its injectable counterpart in clinical trials. This new option aims to expand access for patients who prefer not to use injections.

wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity and related metabolic issues. Experts emphasize it's not a quick fix but a tool to improve insulin function, reduce cardiac events, and aid those with diabetes and PCOS when combined with lifestyle changes.

Novo Nordisk has launched wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, wegovy is a once-weekly injectable using a user-friendly FlexTouch pen. Targeting India's large obese population, Novo Nordisk aims to capture a significant share of the ₹576 crore anti-obesity market.

Novo Nordisk's wegovy, a weight loss drug, will soon be accessible to US customers via telehealth platforms like Hims & Hers, LifeMD, and Ro, offering a reduced monthly price of $449.

Novo Nordisk has launched wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.

Ozempic, Mounjaro and wegovy are now cultural symbols of weight loss. These medications help control blood sugar and aid weight loss. Ozempic is for type 2 diabetes. Mounjaro targets two hormone pathways for stronger sugar and weight control. wegovy is for obesity and related health issues. The choice depends on individual goals and medical history.

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took wegovy

A new study has revealed that GLP-1 drugs, commonly used for diabetes and weight loss, show promise in treating alcohol addiction. The research, published in JAMA Psychiatry, found that semaglutide and liraglutide may reduce alcohol cravings by influencing the brain's reward system.

A recent study presented at the EASD meeting in Vienna reveals that weight loss drugs like Ozempic, wegovy, and Mounjaro can alter taste perception. Around one in five users reported heightened sensitivity to sweetness or saltiness. Researchers suggest these taste changes may contribute to appetite control, potentially aiding in tailored dietary advice and improved treatment outcomes.

Novo Nordisk A/S is considering raising the sales guidance for its obesity drugs after a strong introduction for its new medication called wegovy, chief executive officer (CEO) Lars Fruergaard Jorgensen said in an interview.

Groundbreaking GLP-1 drugs like Ozempic, Mounjaro and wegovy are revolutionising weight loss, with studies showing significant results. While US prices are steep, Indian costs are considerably lower, making them accessible but still a substantial investment. Experts emphasize that these are not magic bullets, requiring ongoing use and medical guidance, raising questions about long-term affordability and access.